Head-To-Head Contrast: Biocorrx (OTCMKTS:BICX) vs. HealthEquity (NASDAQ:HQY)

HealthEquity (NASDAQ:HQY) and Biocorrx (OTCMKTS:BICX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

99.6% of HealthEquity shares are owned by institutional investors. 1.5% of HealthEquity shares are owned by company insiders. Comparatively, 21.4% of Biocorrx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for HealthEquity and Biocorrx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	0	3	10	1	2.86
Biocorrx	0	1	0	0	2.00

HealthEquity currently has a consensus price target of $119.00, suggesting a potential upside of 14.82%. Given HealthEquity’s stronger consensus rating and higher possible upside, research analysts plainly believe HealthEquity is more favorable than Biocorrx.

Earnings & Valuation

This table compares HealthEquity and Biocorrx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.27 billion	7.04	$96.70 million	$1.65	62.81
Biocorrx	$10,000.00	757.76	-$5.11 million	($0.32)	-1.00

HealthEquity has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HealthEquity and Biocorrx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HealthEquity	11.49%	12.04%	7.44%
Biocorrx	N/A	N/A	-96.39%

Volatility & Risk

HealthEquity has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500.

Summary

HealthEquity beats Biocorrx on 13 of the 15 factors compared between the two stocks.

About HealthEquity

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

About Biocorrx

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.